BRIEF-Valeant Pharmaceuticals restates Q4 results after review
April 29 (Reuters) - Valeant Pharmaceuticals
* Restates q4 results after review; now says q4 gaap loss per share $1.12; co on march 15 reported q4 gaap loss per share of $0.98
* Majority of q4 restatement impact attributed to adjustments relating to deferral of addyi revenue, adjustments to returns reserve of xifaxan
* Q4 restatement impact also attributed to including increased professional service fees and intellectual property related adjustments
* As a result of ongoing analysis and review, reports q4 adjusted earnings per share $1.55; co on march 15 reported q4 adjusted earnings per share of $2.50 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
© Thomson Reuters 2017 All rights reserved.